â€oe¿ the article by Moncrieff et a! (1996) about the significance of sexual abuse in people rwith alcohol problems. We, too, have done @search on the relationship of adverse â€˜¿ sexual, physical and emotional childhood Since becoming depressed his libido was non-existent and he had not had any sexual contact. His depression was resistant to treatment with a series of antidepressants. He was commenced on a combinationof lithiumand venlafaxine.
A week after venlafaxine was increased to 375 mg/day, he reported increased libido, much higher than premorbid levels, and frequent spontaneous erections, while conti nuing to be depressed. After six weeks on the same medication, this side-effect gradually waned and his depression improved.
Venlafaxine's unique properties of sero tonin and noradrenaline reuptake inhibition were probably responsible for this side effect. Noradrenaline facilitates libido and erections (Pfaus & Everitt, 1995) and the faciitatory effects of serotonin on sexual function become manifest only when central noradrenaline activity is intact (Fernandez Guasti et a!, 1986).
The literature on beneficial sexual side effects of antidepressants is scanty. Power Smith (1994) reported increased libido, improved erections and improvement in premature ejaculations in two elderly men treated with fluoxetine. Increased libido has been reported with nomifensine, which inhibits reuptake of noradrenaline and dopamine (Freed, 1983) . Mianserin and trazodone, which increase synaptic nora drenaline, improve libido and erections in one-third and two-thirds of subjects, respectively (Kurt et a!, 1994 The Committee on Safety of Medicines in the UK has received 246 reports of suspected extrapyramidal reactions in asso ciation with the use of paroxetine but only three of these reports were of chorea A 37-year-old man was hospitalised because of an exacerbation of refractory schizophrenia.
Clozapine therapy was initiated. During the second week of treat ment the peripheral blood eosinophil level reached up to 700 cells/mm3. The eosino philia persisted for seven weeks with no significant change. There were no accom panying allergic symptoms during this period.Eightweeks afterthe commencement of clozapine the patient was readmitted with high fever and chills. During a careful physical examination a small perianal abscess was detected. Severe agranulocytosis was recorded, which necessitated clozapine discontinuation and the administration of wide-spectrum antibiotics with concurrent granulocyte-colony stimulating factor therapy. A relative abundance of eosinophils was recorded during the patient's neutro penic crisis. Three weeks later the patient's granulocyte count returned to a normal level and he was discharged.
Eosinophilia appears in 0.2â€"1.0% of patients treated with clozapine. Eosinophilia usually occurs early in therapy, and women seem to be at a higher risk (Banov et a!, 1993). The observation of concomitant eosinophilia and paralleling neutropenia has been described in immune deficiencies, bacterial and viral infections, drug reactions and cyclic neutropenia (Tebbi et a!, 1980) . It has been suggested that the addition of anti eosinophilic serum promotes colony forma tion in bone marrow cultures (Tebbi et a!, 1980) . Kurland et a! (1978) proposed that the inhibitory effect of eosinophils is mediated by the secretion of prostaglandin E in the bone marrow. This effect was shown to be abrogated by pre-incubation of eosinophils with indomethacin (Tebbi et a!, 1980) . This occurrence may reflect a controlled regulatory negative feedback between granulocyte-colony stimulating factor and prostaglandin E influences.
In conclusion, we believe that the emergence of agranulocytosis is not coin cidental following eosinophilia appearance during clozapine therapy. More attention should be addressed to eosinophilia in clozapine-treated patients.
